You are right, Cipla has secured approval from the DCGI to import Moderna COVID-19 vaccines for restricted emergency use in India. Under the extant rules, Cipla will have to submit 7 days safety assessment data of the vaccine administered to the first 100 beneficiaries before rolling it out on a mass scale.
This 7 days safety assessment was stipulated to speed up the roll out of vaccines in India when it is already approved by US-FDA for emergency use. Moderna will be the fourth COVID-19 vaccine available in India after Covishield of Astra Zeneca, Covaxin of Bharat Biotech and Sputnik of RDIF, Russia.
You are right, Cipla has secured approval from the DCGI to import Moderna COVID-19 vaccines for restricted emergency use in India. Under the extant rules, Cipla will have to submit 7 days safety assessment data of the vaccine administered to the first 100 beneficiaries before rolling it out on a mass scale.
This 7 days safety assessment was stipulated to speed up the roll out of vaccines in India when it is already approved by US-FDA for emergency use. Moderna will be the fourth COVID-19 vaccine available in India after Covishield of Astra Zeneca, Covaxin of Bharat Biotech and Sputnik of RDIF, Russia.